Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.36 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399249 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3MAPK1 | |
| SCHEMBL30040600 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3MAPK1 | |
| SCHEMBL30110916 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3MAPK1 | |
| SCHEMBL31050860 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3MAPK1 | |
| SCHEMBL22440590 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3MAPK1 | |
| SCHEMBL24097165 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3MAPK1 | |
| SCHEMBL22793052 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3MAPK1 | |
| SCHEMBL21852133 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3MAPK1 | |
| SCHEMBL22309387 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3MAPK1 | |
| SCHEMBL29832891 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | disclosed |
| EP-4368625-A1 | SHP2 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-05-15 | — | — | EP | disclosed |
| CN-117209470-A | SHP2 phosphatase allosteric inhibitor | 北京盛诺基医药科技股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117209471-A | SHP2 phosphatase allosteric inhibitor | 北京盛诺基医药科技股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117209475-A | SHP2 phosphatase allosteric inhibitor | 北京盛诺基医药科技股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| WO-2020249079-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | 北京盛诺基医药科技股份有限公司 | 2020-12-17 | — | — | WO | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN2 | CHRM2 4835/4885CHRM4 4736/4885CHRM1 4851/4885 |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | CHRM2 4866/4885CHRM4 4834/4885CHRM1 4872/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | CHRM2 4835/4885CHRM4 4736/4885CHRM1 4851/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | CHRM2 4862/4885CHRM4 4837/4885CHRM1 4870/4885 |
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | PTPN22, PTPN2, PTPN5 | CHRM2 3665/4885CHRM4 4532/4885CHRM1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.